<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384735</url>
  </required_header>
  <id_info>
    <org_study_id>TOSS</org_study_id>
    <nct_id>NCT00384735</nct_id>
  </id_info>
  <brief_title>An Adequate Cost Effective Follow Up Protocol For Bone &amp; Soft Tissue Sarcomas - A Prospective Randomized Trial</brief_title>
  <acronym>TOSS</acronym>
  <official_title>An Adequate Cost Effective Follow Up Protocol For Bone &amp; Soft Tissue Sarcomas - A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terry Fox Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Terry Fox Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact on overall survival of an intensive&#xD;
      follow-up protocol (as practiced today at TMH) against a more cost effective follow-up&#xD;
      protocol in patients operated for extremity sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow up studies are performed for a variety of reasons. The detection of a recurrence of&#xD;
      the index lesion is the foundation of surveillance. Detection of other medical conditions is&#xD;
      a secondary benefit. Psychologically, follow up testing can serve as a source of reassurance.&#xD;
      Whether an increased frequency of follow up and the use of various expensive imaging&#xD;
      modalities for screening and early detection of recurrence actually results in improving&#xD;
      overall survival of patients with extremity sarcomas is a question that remains as yet&#xD;
      unanswered. Currently followed post -operative surveillance regimes are empirical and vary&#xD;
      widely from centre to centre. Allocation of limited health funding should be guided by&#xD;
      evidence based recommendations rather than empirical beliefs. An ideal surveillance regime&#xD;
      should meet the criteria of easy implementation, accuracy and cost effectiveness.&#xD;
&#xD;
      In a vast country like India where patients often travel thousands of kilometers in their&#xD;
      search for quality medical care the frequency of routine follow up visits is as important as&#xD;
      studying the role of expensive screening modalities while drawing up guidelines for cost&#xD;
      effective follow up strategies.&#xD;
&#xD;
      This study, a prospective randomized controlled trial, attempts to outline guidelines&#xD;
      regarding the role of follow up vis a vis frequency and the use of various imaging modalities&#xD;
      for early detection of recurrence in improving overall survival of patients with extremity&#xD;
      sarcomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2006</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">June 30, 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Minimum 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Minimum 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <description>Intensive - 3 monthly follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <description>Intensive - 6 monthly follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIA</arm_group_label>
    <description>Cost Effective - 3 monthly follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIB</arm_group_label>
    <description>Cost Effective - 6 monthly follow up</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated for primary or recurrent extremity bone &amp; soft tissue sarcomas&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients operated for primary or recurrent extremity bone &amp; soft tissue sarcomas.(both&#xD;
             limb salvage and amputations)&#xD;
&#xD;
          2. Non Metastatic at presentation.&#xD;
&#xD;
          3. Patients reliable for follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-extremity sarcomas.&#xD;
&#xD;
          2. Metastatic at presentation&#xD;
&#xD;
          3. Patients unreliable for follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ajay Puri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tata Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 4, 2006</study_first_submitted>
  <study_first_submitted_qc>October 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Terry Fox Foundation</investigator_affiliation>
    <investigator_full_name>Dr. Ajay Puri</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>bone tumor</keyword>
  <keyword>soft tissue tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

